how much fish oil is too much

How Much Fish Oil Is Too Much?

Fish oil is an indisputable ally in your fat loss efforts.

Actually, to be fair, there isn’t any condition that is not improved by the consumption of fish oil.

But when it comes to fat loss, fish oil shows up with an impressive curriculum. Indeed it:

  • Improves cellular communication
  • Improves insulin sensitivity
  • Reduces inflammation
  • Favors lean mass

This is a wide-ranging array of bold claims, let’s explore each one

Improves cellular communication

Each cell in your body is surrounded by a lipid bilayer. This membrane contains various lipids including cholesterol and phospholipids. Cholesterol is a somewhat rigid molecule. Similarly, saturated phospholipids due to their straight physical conformation make the membrane more dense and compact. Hence the ratio between cholesterol and saturated phospholipids vs unsaturated phospholipids dictates the membrane fluidity.

Why would this matter?

Because the ability of a cell to communicate with the external milieu depends on its malleability. One thing to keep in mind is that cell membranes function according to what is called a fluid mosaic model. Transporter proteins, ion channels, signalling proteins, and a whole array of cellular substructures need to navigate from the cell to the outer surface of the membrane in order for the cell to function properly.

From a fat-loss perspective, you want the adipocytes to be receptive to signals inducing fatty acid liberation, otherwise the adipocytes will never release their stored bounty.

Improves insulin sensitivity

This point ties in with the previous one; it is a specific case of cellular communication since insulin sensitivity is receptor-dependent. And insulin is arguably one critical factor for body composition. In fact, it is one of the single most important factor 100% under your control to manage your health, wellness and body composition.

Reduces inflammation

Acute inflammation is normal and desirable as it allows the body to heal itself. On the other hand, chronic inflammation creates all sorts of inconveniences – one of them being to stall fat loss.

Inflammation prevents fat loss by a variety of factors such as disruptions of the thyroid hormonal cascade, development of oestrogen toxicity and impaired insulin sensitivity. Suffice it to say that in a situation of chronic inflammation, your body’s top priority is not to get rid of your muffin top, it is to survive. Period.

Once the crisis is under control, then, your metabolism can revert to its usual fare.

  • Turns on lipolytic genes
  • Turns off lipogenic genes

These two points are pretty self-explanatory: lipolytic means fat breaking, and lipogenic means fat making. Recently it has come to the public knowledge that gene expression can be modulated by the environment. In the case of the fat storing/fat burning genes, their expression can be modulated – as with a dimmer. Less fat storing, more fat burning.

Favors lean mass

Fish oil also appears to be anti-catabolic, meaning that it spares muscle. The body is in a constant state of building and destroying tissues, and muscle is no different in this regard. This balance of anabolism (building) and catabolism (destroying) must be tipped toward anabolism if you want to gain muscle mass. Slowing down catabolism in regard to anabolism is the second part of the equation, but it’s one seldom considered.

The advantage of fish oil is that it seems to be doing both, as it has been shown to decrease the activity of the system that mediates muscle degradation, called ubiquitin-proteasome system. EPA is the fatty acid that reduce the activity of this system significantly. Hence an EPA-rich supplement might be more adequate to reduce catabolism.

Sadly, it takes a lot of fish oil to reach the full benefits. The best fat loss effect is obtained with a dose of  50g/day…

… At such high dosage, supplementation becomes pricey and compliance a problem (and not only from haters and doubters)…

This is one of the many reasons I formulated Omega Drive as a solution to this issue!

Omega Drive… When Less Is More

 

  • Omega Drive solves the problem of high quantities since you only need 1/3 of the dosage
  • Plus, omega drive is very effective when combined with glutamine and probiotics in reducing joint pain with certain clients such as people suffering from any type of inflammatory disease i.e osteoarthritis.
  • Same goes with high blood pressure issues where very good results have been observed.
  • Plus, in the animal model it reduces the risk of 4 types of cancer: colo-rectal, prostate, breast, liver.

BUY NOW,

click the picture HERE

 

Read on for the science part!

MaxSimil® Patented Lipid Absorption Enhancement Technology (PLATform)

The MaxSimil PLATform is a novel monoglyceride delivery system that enhances absorption of lipid-based and lipid-soluble nutraceutical and food ingredients. This technology has been applied to Omega-3 rich fish oils in order to create a unique vehicle by which to deliver EPA and DHA.

Due to the fact that monoglyceride oils are intrinsically emulsifiers and are, by nature, in a readily absorbable form (Figure 1), they can bypass the body’s normal fat digestion process.

These qualities make MaxSimil Fish Oils an excellent method for delivering omega-3 fatty acids, especially to individuals with digestive, pancreatic, or gall bladder challenges.

Studies show that MaxSimil fish oils (FO) have three times (300%) greater absorption of EPA and DHA compared to other leading fish oils.*[1-3]

Figure 1.

omega drive

Monoglyceride Chemical Representation in MaxSimil Omega-3 (R1 = fatty acid)

Unique structure: One fatty acid attached to a glycerol backbone provides two polar ends that attract water and a non-polar tail end (R1) that attracts fat, thus enabling self-emulsification of the MaxSimil Omega-3 formulas.

Reprinted with permission from Ingenutra, Inc.

Quality

MaxSimil Omega-3 formulas are made using proprietary MaxSimil compositions containing monoglyceride FO with no additional ingredients, carriers, or excipients.

Each fish-gelatin softgel is enteric-coated, and every batch of fish oil is IFOS five-star certified to ensure the world’s highest standards for purity, potency, and freshness.

The fish oil is non-GMO, from sustainable fisheries, made in Europe, and antibiotic-free.

Additionally, it is eco-friendly because the greater absorption of EPA and DHA ultimately means that fewer grams of fish oil need to be harvested for the same benefit.*

In Vitro and In Vivo Animal Studies

The ability of MaxSimil-enhanced EPA and DHA to positively influence growth inhibition and apoptosis in colorectal, breast, lung, and prostate diseased cell lines was first demonstrated in a series of in vitro studies.[4-6] Researchers subsequently set out to demonstrate efficacy in animal models after oral administration.

In three separate animal models, MaxSimil EPA and DHA forms showed superior activity on diseased cell-line growth inhibition and cytokine production when compared to control, corn oil, krill oil, or the parent forms ethyl ester (EE) EPA and ethyl ester (EE) DHA.[4,7,8] These in vivo animal studies proved that orally supplemented MaxSimil EPA and DHA were well-absorbed and bioactive. Researchers postulated that the observed superior effects of MaxSimil EPA and DHA forms were the result of enhanced absorption, and they set out to prove this hypothesis.*

Preclinical Bioavailability Studies The in vivo pharmacokinetic studies in rodents involved a comparison between MaxSimil DHA FO and its parent EE DHA FO and an analysis of blood concentrations of DHA over time.

The doses used were equivalent to human doses of 3 g/day and 30 g/day; the latter was included primarily to investigate toxicity at high doses.

Researchers found that MaxSimil DHA FO had a three times (3x) higher peak concentration (6% versus 2%, Figure 2), a 3x higher saturation potential at the high dose (10% versus 3%), and a 3x higher absorption rate (at a 3 g/day equivalent human dose) than its parent DHA FO.

No toxicity was observed at either dose level.[1,2] This research demonstrated superior bioavailability and presumably better exposure of cells to DHA.*

Figure 2.

Preclinical Bioavailability Study in Rodents Demonstrates Superior Peak Concentration, Saturation, and Absorption of MaxSimil DHA FO Versus Its Parent DHA FO

omega 3

Data were derived from Ingenutra, Inc.[1,2]

Clinical Bioavailability Study

A phase 1, double-blind, randomized, crossover, pharmacokinetic study was performed in 20 healthy adults aged between 19 and 71 years who were administered 6 g (containing 1800 mg EPA and 1200 mg DHA) per day of EE FO or MaxSimil FO.[3] Parameters studied were plasma EPA and DHA concentration (as percent of total fatty acids), Cmax, and AUC. Compared to EE EPA+DHA, the results indicated that at peak concentration, MaxSimil EPA and DHA forms were 3x higher, they reached maximum concentration faster, and maintained their plasma levels longer (Figure 3).

The finding in the animal study was validated: the MaxSimil FO instantaneous absorption was 3x greater than the EE form. Likewise, the AUC over 24 hours was also more than 3x higher (P<0.0001) for MaxSimil EPA and DHA (MaxSimil FO).*

Not only did this study confirm the bioavailability findings in the animal study, but it also demonstrated that after 24 hours, the MaxSimil FO maintained 2-3x higher blood levels of EPA and DHA than the EE FO. This means that, given a daily dose, circulating EPA and DHA levels can be expected to ramp up over time and remain high with steadily increasing exposure of cells to EPA, DHA, and their metabolites.

Based on the results of the bioavailability studies, an individual would get more EPA and DHA from MaxSimil FO than from EE FO gram for gram. Furthermore, as shown in the animal studies, one could anticipate enhanced effects. It is noteworthy that all 20 adults who completed the study saw their omega-3 absorption enhanced when taking the MaxSimil enhanced FO.*

Figure 3.

Human Clinical Study Findings Demonstrate Superior Absorption of and Exposure to EPA and DHA as Indicated by Cmax, Tmax, and AUC

omega 3

Reprinted with permission from Ingenutra, Inc.

Expanding Research

In vitro and animal studies have demonstrated the positive effects of MaxSimil FO on airway immune response (e.g., IgE, leukocytes); the expression of COX-2, NF-kB, cytokines (e.g., IL-6, IL-8), MUC5AC, and mucin; and Ca(2+) hypersensitivity in lung tissues.[8-11]

In other research, rats subjected to eight weeks of a high-fat, high-carbohydrate diet were either not supplemented or provided 3 g/day of MaxSimil DHA.

Compared to the data from the non-supplemented group, the data from the MaxSimil DHA supplemented group clearly showed a positive impact on cardiovascular health parameters. Measures included blood pressure, heart rate, serum lipid levels, cytokine production, aortic wall thickness, and a DHA:AA ratio in aortic tissue, which correlated with the production of resolvin D2 and D3 metabolites.*[12]

BUY NOW,

click the picture HERE

References

  1. Unpublished, internal data. Ingenutra.
  2. Fortin S, inventor; Centre de Recherche sur les Biotechnologies Marines, assignee. Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof. US patent 8,198,324. June 12, 2012.
  3. MaxSimil Patented Lipid Absorption Technology Clinical Study Report: MaxSimil® 3020 Omega-3. Sherbrooke (Québec), Canada: Ingenutra; 2015. [Unpublished, internal data]
  4. Morin C, Rousseau É, Fortin S. Anti-proliferative effects of a new docosapentaenoic acid monoacylglyceride in colorectal carcinoma cells. Prostaglandins Leukot Essent Fatty Acids. 2013 Sep;89(4):203-13. [PMID: 23932824]
  5. Fortin S, inventor; Centre de Recherche sur les Biotechnologies Marines, assignee. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof. US patent 8,119,690. February 21, 2012.
  6. Fortin S, inventor; Centre de Recherche sur les Biotechnologies Marines, assignee. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof. US patent 8,329,747. December 11, 2012.
  7. Morin C, Blier PU, Fortin S. Eicosapentaenoic acid and docosapentaenoic acid monoglycerides are more potent than docosahexaenoic acid monoglyceride to resolve inflammation in a rheumatoid arthritis model. Arthritis Res Ther. 2015 May 29;17:142. [PMID: 26022389]
  8. Morin C, Fortin S, Cantin AM, et al. Docosahexaenoic acid derivative prevents inflammation and hyperreactivity in lung: implication of PKC-Potentiated inhibitory protein for heterotrimeric myosin light chain phosphatase of 17 kD in asthma. Am J Respir Cell Mol Biol. 2011 Aug;45(2):366-75. [PMID: 21057106]
  9. Morin C, Fortin S, Cantin AM, et al. MAG-EPA resolves lung inflammation in an allergic model of asthma. Clin Exp Allergy. 2013 Sep;43(9):1071-82. [PMID: 23957343]
  10. Morin C, Cantin AM, Rousseau É, et al. Pro-resolving action of MAG-DHA in lung inflammatory models related to cystic fibrosis. Am J Respir Cell Mol Biol. 2015 Oct;53(4):574-83. [PMID: 25781052]
  11. Morin C, Fortin S, Rousseau É. New omega-3 derivatives reduce airway inflammation and prevent rho-kinase activation in an allergic model of asthma. J Aller Ther. 2012;3(S1):003. doi:10.4172/2155-6121.S1-003.
  12. Morin C, Rousseau E, Blier PU, et al. Effect of docosahexaenoic acid monoacylglyceride on systemic hypertension and cardiovascular dysfunction. Am J Physiol Heart Circ Physiol. 2015 Jul 1;309(1):H93-H102. [PMID: 25910811]
  13. Weylandt KH, Chiu CY, Gomolka B, et al. Omega-3 fatty acids and their lipid mediators: towards an understanding of resolvin and protectin formation. Prostaglandins Other Lipid Mediat. 2012 Mar;97(3-4):73-82. [PMID: 22326554]
  14. Guasch-Ferré M, Hu FB, Martínez-González MA, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013 Apr 4;368(14):1279-90. [PMID: 23432189]
  15. Mayor S. Mediterranean diet reduces cardiovascular events in people with heart disease, study shows. BMJ. 2016 Apr 24;353:i2348. [PMID: 27114468]
  16. Chiva-Blanch G, Badimon L, Estruch R. Latest evidence of the effects of the Mediterranean diet in prevention of cardiovascular disease. Curr Atheroscler Rep. 2014 Oct;16(10):446. [PMID: 25115436]
  17. Fitó M, Cladellas M, de la Torre R, et al. Anti-inflammatory effect of virgin olive oil in stable coronary disease patients: a randomized, crossover, controlled trial. Eur J Clin Nutr. 2008 Apr;62(4):570-74. [PMID: 17375118]
  18. Ruano J, López-Miranda J, de la Torre R, et al. Intake of phenol-rich virgin olive oil improves the postprandial prothrombotic profile in hypercholesterolemic patients. Am J Clin Nutr. 2007 Aug;86(2):341-46. [PMID: 17684203]
  19. Gimeno E, de la Torre-Carbot K, Lamuela-Raventós RM, et al. Changes in the phenolic content of low density lipoprotein after olive oil consumption in men. A randomized crossover controlled trial. Br J Nutr. 2007 Dec;98(6):1243-50. [PMID: 17617938]
  20. Bogani P, Galli C, Villa M, et al. Postprandial anti-inflammatory and antioxidant effects of extra virgin olive oil. Atherosclerosis. 2007 Jan;190(1):181-86. [PMID: 16488419]
  21. Guasch-Ferré M, Hu FB, Martínez-González MA, et al. Olive oil intake and risk of cardiovascular disease and mortality in the PREDIMED Study. BMC Med. 2014 May 13;12:78. [PMID: 24886626]
  22. Castañer O, Covas MI, Khymenets O, et al. Protection of LDL from oxidation by olive oil polyphenols is associated with a downregulation of CD40-ligand expression and its downstream products in vivo in humans. Am J Clin Nutr. 2012 May;95(5):1238-44. [PMID: 22440854]
  23. Raederstorff D. Antioxidant activity of olive polyphenols in humans: a review. Int J Vitam Nutr Res. 2009 May;79(3):152-65. [PMID: 20209466]